Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal

Neurobiology of Aging

Volumn 17, Issue 5, 1996, Pages 789-794

  Breitner, John C S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Antiinflammatory drugs; Corticosteroids; Glucocorticoids; Inflammation; Nonsteroidal antiinflammatory drugs (NSAIDs); Prevention; Treatment

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

ALZHEIMER DISEASE; DRUG EFFECT; DRUG EFFICACY; HUMAN; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; REVIEW;

EID: 0030250376     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-4580(96)00109-1     Document Type: Article

References (93)

1. 1. Abraham, C. R.; Selkoe, D. J.; Potter, H. Immunohistochemical identification of the serine protease inhibitor alpha-1 antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52:487-501; 1988.
2. 2. Aisen, P. S. Anti-inflammatory therapy for Alzheimer's disease. Dementia 9:173-182; 1995.
3. 3. Aisen, P. S.; Davis, K. L. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am. J. Psychiatry 151:1105-1113; 1994.
4. 4. Altstiel, L.; Sperber, K. Cytokines in Alzheimer's disease. Biol. Psychiatry 15:481-495; 1991.
5. 5. Andersen, K.; Launer, L. J.; Ott, A.; Hoes, A. W.; Breteler, M. M. B.; Hofman, A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45:1441-1445; 1995.
6. 6. Ban, E. M. Interleukin-1 receptors in the brain: Characterization by quantitative in situ autoradiography. Immunomethods 5:31-40; 1994.
7. 7. Banati, R. B.; Gehrmann, J.; Schubert, P.; Kreutzberg, G. W. Cytotoxicity of microglia. Glia 7:111-118; 1993.
8. 8. Bauer, J. Interleukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer's disease cortices. FEBS Lett. 285:111-114; 1991.
9. 9. Bauer, J.; Ganter, U.; Strauss, S.; et al.. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res. Immunol. 143: 650-657; 1992.
10. 10. Breitner, J. C. S. Clinical genetics and genetic counseling in Alzheimer's disease. Ann. Intern. Med. 115:601-606; 1991.
11. 11. Breitner, J. C. S. New epidemiologic strategies in Alzheimer's disease may provide clues to prevention and cause. Neurobiol. Aging 150:S175-S177; 1994.
12. 12. Breitner, J. C. S.; Gau, B. A.; Welsh, K. A.; et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 44:227-232; 1994.
13. 13. Breitner, J. C. S.; Welsh, K. A.; Helms, M. J.; et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 16:523-530; 1995.
14. 14. Breteler, M. M. B.; Claus, J. J.; van Duijn, C. M.; Launer, L. J.; Hofman, A. Epidemiology of Alzheimer's disease. Epidemiol. Rev. 14: 59-82; 1992.
15. 15. Breteler, M. M. B.; van Duijn, C. M.; Chandra, V.; et al. Medical history and the risk of Alzheimer's disease: A collaborative reanalysis of case-control studies. Int. J. Epidemiol. 20(Suppl. 2):S36-S42; 1991.
16. 16. Broe, G. A.; Henderson, A. S.; Creasey, H.; et al. A case-control study of Alzheimer's disease in Australia. Neurology 40:1698-1707; 1990.
17. 17. Choi, D. W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634; 1988.
18. 18. Chui, D.H.; Tabira, T.; Izumi, S.; Koya, G.; Ogata, J. Decreased β-amyloid and increased abnormal tau deposition in the brain of aged patients with leprosy. Am. J. Pathol. 145:771-775; 1994.
19. 19. Colton, A.C.; Gilbert, D. L. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 223:284-288; 1987.
20. 20. Corder, E. H.; Saunders, A. M.; Strittmatter, W. J.; et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923; 1993.
21. 21. Cordell, B. B-Amyloid formation as a potential therapeutic target for Alzheimer's disease. Annu. Rev. Pharmacol. Toxicol. 34:69-89; 1994.
22. 22. Corradin, S. B.; Mauel, J.; Donini, S. D.; Quattrocchi, E.; Castagnoli, P. R. Inducible nitric oxide synthase activity of cloned murine microglial cells. Glia 7:255-262; 1993.
23. 23. Eikelenboom, P.; Hack, C. E.; Rozemuller, J. M.; Stam, F. C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. B. Cell Pathol. 56:259-262; 1989.
24. 24. Einstein, G.; Bautista, P.; Patel, V.; et al. Distribution of apoE-immunoreactive neurons in control and AD brains. Soc. Neurosci. Abstr. 21:1008; 1995.
25. 25. Fillit, H.; Ding, W.; Buee, L.; et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129:318-320; 1991.
26. 26. Fratiglioni, L. Epidemiology of Alzheimer's disease. Issues of etiology and validity. Acta Neurol. Scand. 87(Suppl. 145): 1-7; 1993.
27. 27. Frederickson, R. C. A. Astroglia in Alzheimer's disease. Neurobiol. Aging 13:239-253; 1992.
28. 28. Frederickson, R. C. A.; Brunden, K. R. New opportunities in AD research - Roles of immunoinflammatory responses and glia. Alzheimer Dis. Assoc. Disorders 8:159-165; 1994.
29. 29. Giulian, D. Reactive glia as rivals in regulating neuronal survival. Glia 7:102-110; 1993.
30. 30. Goldgaber, D.; Harris, H. W.; Hla, T.; et al. Interleukin-1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA 86:7606-7610; 1989.
31. 31. Gottschall, P. E.; Tatsuno, I.; Arimura, A. Regulation of interleukin-6 (IL-6) secretion in primary cultured rat astrocytes: Synergism of interleukin-1 (IL-1) and pituitary adenylate cyclase activating polypeptide (PACAP). Brain Res. 637:197-203; 1994.
32. 32. Graves, A. B.; White, E.; Koepsell, T. D.; et al. A case-control study of Alzheimer's disease. Ann. Neurol. 28:766-774; 1990.
33. 33. Graves, A. B.; White, E.; Koepsell, T. D.; et al. The association between head trauma and Alzheimer's disease. Am. J. Epidemiol. 131: 491-501; 1990.
34. 34. Griffin, W. T. S.; Stanley, L. C.; Ling, C.; et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA 86:7611-7615; 1989.
35. 35. Haga, S.; Ikeda, K.; Sata, M.; Ishii, T. Synthetic Alzheimer amyloid/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res. 601:88-94; 1993.
36. 36. Hansen, L. A.: DeTeresa, R.; Davies, P.; Terry, R. D. Neocortical morphometry, lesion counts and choline acetyltransferase levels in the age spectrum of Alzheimer's disease. Neurology 38:48-54; 1988.
37. 37. Hebert, L. E.; Scherr, P. A.; Beckett, L. A.; et al. Relation of smoking and alcohol consumption to incident Alzheimer's disease. Am. J. Epidemiol. 135:347-355; 1992.
38. 38. Henderson, A. S. Epidemiology of dementing disorders. In: Wurtman, R. J.; Growdon, J. H.; Corkin, S.; et al. eds. Alzheimer's disease. New York: Raven Press; 1990:15-25.
39. 39. Henderson, A. S.; Jorm, A. F.; Korten, A. E.; et al. Environmental risk factors for Alzheimer's disease: Their relationship to age of onset and to familial or sporadic types. Psychol. Med. 22:429-436; 1992.
40. 40. Heyman, A.; Wilkinson, W. E.; Stafford, J. A.; Helms, M. J.; Sigmon, A. H.; Weinberg, T. Alzheimer's disease: A study of epidemiological aspects. Ann. Neurol. 15(4):335-341; 1984.
41. 41. Holstein, J.; Chatellier, G.; Piette, F.; Moulias, R. Prevalence of associated diseases in different types of dementia among elderly institutionalized patients; Analysis of 3447 records. J. Am. Geriatr. Soc. 42:972-977; 1994.
42. 42. Jenkinson, M. L.; Bliss, M. R.; Brain, A. T.; Scott, D. L. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br. J. Rheumatol. 28:86-88; 1989.
43. 43. Jorm, A. F.; van Duijn, C. M.; Chandra, V.; et al. Psychiatric history and related exposures as risk factors for Alzheimer's disease: A collaborative reanalysis of case-control studies. Int. J. Epidemiol. 20(Suppl. 2):S43-S47; 1991.
44. 2 in rat astrocyte cultures: Modulatory effect of neuropeptides. Endocrinology 124:3125-3127; 1989.
45. 45. Katzman, R.; Terry, R.; DeTeresa, R.; et al. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23:138-144; 1988.
46. 46. Koh, J. Y.; Yang, L. L.; Cotman, C. W. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:315-320; 1990.
47. 47. Kukull, W. A.; Larson, E. B.; Stergachis, A.; et al. Nonsteroidal anti-inflammatory drug use and risk of Alzheimer's disease. Neurology 44(Suppl. 2):A237; 1994.
48. 48. Lerea, L. S.; McNamara, J. O. Inotropic glutamate receptor subtypes activate c-fos transcription by distinct calcium-requiring intracellular signaling pathways. Neuron 10:31-441; 1993.
49. 49. Li, G.; Shen, Y. C.; Li, Y. T.; Chen, C. H.; Zhau, Y. W.; Silverman, J. M. A case-control study of Alzheimer's disease in China. Neurology 42:1481-1488; 1992.
50. 50. Lucca, U.; Tettamanti, M.; Forloni, G.; Spagnoli, A. Nonsteroidal anti-inflammatory drug use in Alzheimer's disease. Biol. Psychiatry 36:854-856; 1994.
51. 51. Lue, L. F.; Rogers, J. Full complement activation fails in diffuse plaques of the Alzheimer's disease cerebellum. Dementia 3:308-313: 1992.
52. 52. Madison, D. V.; Malenka, R. C.; Nicoll, R. A. Mechanisms underlying long-term potentiation of synaptic transmission. Annu. Rev. Neurosci. 14:379-397; 1991.
53. 53. Mayeux, R.; Ottman, R.; Maestre, G.; et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 45:555-557; 1995.
54. 54. Mayeux, R.; Ottman, R.; Tang, M.-X.; et al. Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community-dwelling elderly persons and their first-degree relatives. Ann. Neurol. 33:494-501; 1993.
55. 55. McDowell, I.; Hill, G.; Lindsay, J.; et al. The Canadian study of health and aging: Risk factors for Alzheimer's disease in Canada. Neurology 44:2073-2080; 1994.
56. 56. McGeer, P. L.; Akiyama, H.; Itagaki, S.; McGeer, E. G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:516-527; 1989.
57. 57. McGeer, P. L.; Harada, N.; Kimura, H.; McGeer, E. G.; Schulzer, M. Prevalence of dementia amongst elderly Japanese with leprosy apparent effect of chronic drug therapy. Dementia 3:146-149; 1992.
58. 58. McGeer, P. L.; Kawamata, T.; Walker, D. G.; Akiyama, H.; Tooyama, I.; McGeer, E. G. Microglia in degenerative neurological disease. Glia 7:84-92; 1993.
59. 59. McGeer, P. L.; McGeer, E. G. Chronic inflammatory mechanisms of the brain: Implications for the treatment of Alzheimer disease. Dementia 9:111-123; 1995.
60. 60. McGeer, P. L.; McGeer, E.; Rogers, J.; Sibley, J. Anti-inflammatory drugs and Alzheimer disease. Lancet 335:1037; 1990.
61. 61. McGeer, P. L.; Rogers, J.; McGeer, E. G. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis. Assoc. Disord. 8:149-158; 1994.
62. 62. Mortimer, J. A. Presented at the Annu. Meet. Am. Psychopathol. Assoc., New York, NY; 1995.
63. 63. Mortimer, J. A.; van Duijn, C. M.; Chandra, V.; et al. Head trauma as a risk factor for Alzheimer's disease: A collaborative reanalysis of case-control studies. Int. J. Epidemiol. 20(Suppl. 2):S28-S35; 1991.
64. 64. Mrak, R. E.; Sheng, J. C.; Griffin, W. S. Glial cytokines in Alzheimer's disease: Review and pathogenetic implications. Hum. Pathol. 26:816-823; 1995.
65. 65. Myllykangas-Luosujarvi, R.; Isomaki, H. Alzheimer's disease and rheumatoid arthritis. Br. J. Rheumatol. 33:501-502; 1994.
66. 66. Nietro-Sampredo, M. Astrocyte mitogenic activity in aged normal and Alzheimer's human brain. Neurobiol. Aging 8:249-252; 1987.
67. 67. Norris, J. G.; Benveniste, E. N. Interleukin-6 production by astrocytes: Induction by the neurotransmitter norepinephrine. J. Neuroimmunol. 45:137-145; 1993.
68. 68. O'Banion, M. K.; Winn, V. D.; Young, D. A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA 89:4888-4892; 1992.
69. 69. Oltersdorf, T.; Frita, L. C.; Schenk, D. B.; Lieberburg, I.; et al. The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature 341:144-147:1989.
70. 70. Steffens, D. C.; Plassman, B. L.; Helms, M. J.; Welsh, K. A.; Saunders, A. M.; Breitner, J. C. S. A twin study of late-onset depression and apolipoprotein E ∈4 as risk factors for Alzheimer's disease. Biol. Psychiatry. (in press).
71. 71. Rich, J. B.; Rasmusson, D. X.; Folstein, M. F.; Carson, K. A.; Kawas, C.; Brandt, J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45:51-55; 1995.
72. 72. Roberts, G. W.; Gentleman, S. M.; Lynch, A.; Murray, L.; Landon, M.; Graham, D. I. β-Amyloid protein deposition in the brain after severe head injury: Implications for the pathogenesis of Alzheimer's disease. J. Neurol. 57:419-4-25; 1994.
73. 73. Rogers, J.; Kirby, L. C.; Hempelman, S. R.; et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609-1611; 1993.
74. 74. Roses, A. D. The Alzheimer diseases. In: Appel, S. H., ed. Current neurology, vol. 14. Chicago: C. V. Mosby Yearbooks; 1994:111-141.
75. 75. Rozemuller, J. M.; Eikelenboom, P.; Pals, S. T.; Stam, F. C. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci. Lett. 101: 288-292; 1989.
76. 76. Rozemuller, J. M.; Stam, F. C.; Eikelenboom, P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci. Lett. 109:75-78; 1990.
77. 77. Rubio, N. Demonstration of the presence of interleukin-1 receptor on the surface of murine astrocytes and its regulation by cytokines and Theiler's virus. Immunology 82:178-183; 1994.
78. 78. Satz, P. Brain reserve capacity on symptom onset after brain injury: A formulation and review of evidence for threshold theory. Neuropsychology 7:273-295; 1993.
79. 79. Schofield, P. W.; Mosesson, R. E.; Stern, Y.; Mayeux, R. The age at onset of Alzheimer's disease and an intracranial area measurement. Arch. Neurol. 52:95-98; 1995.
80. 80. Smeyne, R. J.; Vendrell, M.; Hayward, M.; et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature 363:166-169; 1993.
81. 81. Smith, W. L.; Borgeat, P.; Fitzpatrick, A. F. The eicosanoids: cyclooxygenase, lipoxygenase, and epoxygenase pathways. In: Vance, D. E.; Vance, J., eds. Biochemistry of lipids, lipoproteins and membranes. New York: Elsevier; 1991:297-325.
82. 82. Smith, W. L.; Marnett, L. J. Prostaglandin endoperoxide synthase: Structure and catalysis. Biochim. Biophys. Acta 1083:1-17; 1991.
83. 83. Soil, A. H.; Weinstein, W. M.; Kurata, J.; McCarthy, D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann. Intern. Med. 114(4):307-319; 1991.
84. 84. Stern, Y.; Gurland, B.; Tatemichi, T. K.; Tang, M. X.; Wilder, D.; Mayeux, R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 271:1004-1010; 1994.
85. 85. Strittmatter, W. J.; Weisgraber, K. H.; Goedert, M.; et al. Hypothesis: Microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp. Neurol. 125:163-171; 1994.
86. 86. Sunami, A.; Tasaka, K. Two aspects of the excitatory influence of histamine on hippocampal neurons in guinea pigs. Methods Find. Exp. Clin. Pharmacol. 13:85-91; 1991.
87. 87. van Duijn, C. M.; Tanja, T. A.; Haaxma, R.; et al. Head trauma and the risk of Alzheimer's disease. Am. J. Epidemiol. 135:775-782; 1992.
88. 88. Vane, J. Towards a better aspirin. Nature 367:215-216; 1994.
89. 89. Vane, J.; Hotting, R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J. 11:89-96; 1987.
90. 90. Vaughn, D. M.; Rossmanith, R. C.; Cox, N. R. Eicosanoid-induced inhibition of glutamate uptake in cortical astrocytes. Soc. Neurosci. Abstr. 17:55; 1991.
91. 91. Wagstaff, A. J.; McTavish, D. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 4:510-540; 1994.
92. 92. Walker, D. G.; Kim, S. U.; McGeer, P. L. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J. Neurosci. Res. 40:478-493; 1995.
93. 93. Zhang, M. Y.; Katzman, R.; Salmon, D.; et al. The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education. Ann. Neurol. 27:428-443; 1990.